Tovaxin ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎3

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00595920
(ClinicalTrials.gov)
November 20073/1/2008Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple SclerosisAn Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00Multiple Sclerosis, Relapsing-Remitting;Clinically Isolated SyndromeBiological: TovaxinOpexa Therapeutics, Inc.NULLTerminatedN/AN/AAll116Phase 2United States
2NCT00245622
(ClinicalTrials.gov)
May 200620/10/2005Autologous T Cell Vaccine (TCV) for Multiple SclerosisA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin in Subjects With CIS or RR-MSRelapsing-Remitting Multiple SclerosisBiological: Tovaxin Autologous T cell vaccine;Biological: PlaceboOpexa Therapeutics, Inc.NULLCompleted18 Years55 YearsBoth150Phase 2United States
3NCT00587691
(ClinicalTrials.gov)
July 200221/12/2007Dose-Escalation Study of T Cell Vaccine in Multiple SclerosisAn Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary ProgressiveBiological: Tovaxin Autologous T Cell VaccineOpexa Therapeutics, Inc.NULLCompleted18 Years65 YearsAll16Phase 1/Phase 2United States